Skip to content
Medicines & Healthcare products Regulatory Agency
The National Institute for Biological Standards and Control

Confidence in biological medicines

  • Stay connected
  • Shopping Basket
  • Pay Now
  • Login / Register
  • Home
  • Products
  • Standardisation
  • Control testing
  • Science and research
  • Expert services
  • About us
  • QE2
  • Latest news
  • Worldwide impact of NIBSC
  • Mission and values
  • Careers
  • Quality and governance
  • Staff profiles
  • Contact us
  • Collaborations
  • Suppliers
  • Scientific Advisory Committee
  • Minutes of the Animal Welfare and Ethical Review Body
  • Our use of animals
  • Privacy notice
  • Home  /  
  • About us  /  
  • Staff profiles  /  
  • Sandra S. Diebold

Dr Sandra Diebold

Sandra Diebold studied Biology at the Eberhard Karls University in Tübingen, Germany. She worked with Martin Zenke on the generation of gene-modified dendritic cells for tumour immunotherapy, first at the Institute of Molecular Pathology (IMP) in Vienna, Austria and then at the Max Delbrück Center for Molecular Medicine (MDC) in Berlin, Germany.

As a postdoctoral fellow, Sandra worked at the Cancer Research UK London Research Institute with Caetano Reis e Sousa. Her work there focused on investigating the innate recognition of viruses by dendritic cells via various pattern recognition receptors including the endosomal Toll-like receptors TLR3, TLR7 and TLR9, but also cytoplasmic nucleic acid sensors. Among other projects, Sandra discovered that plasmacytoid dendritic cells sense viral singe-stranded RNA via TLR7 and together with her co-worker Oliver Schulz investigated how the detection of viral double-stranded RNA by TLR3 allows cross-priming dendritic cells to distinguish between virus-infected and uninfected dying cells.

In 2005, Sandra set up her own group in the Immunobiology Department at King’s College London (KCL) funded by a Cancer Research UK Career Development Award. Her group at KCL explored the use of synthetic mimics of viral nucleic acids as adjuvants for tumour immunotherapy. This included the generation and application of antibody-antigen-adjuvant complexes for receptor-targeted co-delivery of antigens and adjuvants to primary dendritic cells in vivo. In addition, her group investigated how to overcome the immunosuppressive effects of the tumour microenvironment, which impair dendritic cell function in the context of ovarian carcinoma.

In 2015, Sandra joined NIBSC as head of the Immunotoxicology Group, which investigates immunotherapeutic antibodies and immunomodulatory reagents and develops in vitro assays for evaluation of their immunotoxicological function. The group also is involved in the generation of in vitro diagnostic material for use as clinical flow cytometry standards. In 2016 Sandra was appointed Section Leader for Cellular Immunology, which also includes the Pyrogen Science Group. In addition, Sandra continues to follow her research interest exploring novel immunotherapeutic approaches for cancer therapy at NIBSC. This includes the investigation of targeted deposition of adjuvants in the tumour tissue in order to overcome local immunosuppression in mouse tumour models.

Current position

Section Leader, Cellular Immunology, Division of Biotherapeutics

Areas of interest
Dendritic cells
Innate immune activation
Endosomal Toll-like receptors
Vaccine adjuvants
Tumour immunotherapy
Immunotoxicology

Qualifications:

1994: Dipl.-Biol., Eberhard Karls University Tübingen, Germany
1999: Dr. rer. nat., Free University Berlin, Germany

Research publications (PDF, 170KB)

Grants secured in the last 10 years

2005 - 2011: Cancer Research UK Career Development Award
2008: Cancer Research UK Equipment Grant
2008 - 2010: 2-Year Project Grant from Innate Pharma
2009 - 2012: 3-Year Cancer Research UK Chinese Postdoctoral Fellow Award
2009 - 2013: 4-Year Cancer Research UK PhD Studentship Award
2013: TRANSVAC Grant (free access to Affymetrix Arrays)

  • Careers
  • Terms and conditions
  • Accessibility
  • Privacy notice
  • Cookies
  • Sitemap